NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

PRLB

Proto Labs Inc. New York Stock Exchange
$160
Open: $151.08 High: $152.5 Low: $144.345 Close: $150
Range: 2021-03-02 - 2021-03-03
Volume: 376,341
Market: Extended-hours
Powered by Finage Stock APIDelayed data
PRLB
Proto Labs Inc. 5540 Pioneer Creek Drive Maple Plain MN, 55359 http://www.protolabs.com
Proto Labs Inc is an online and technology-enabled manufacturer of on-demand three-dimensional printed, computer numerical control machined and injection-molded custom parts for prototyping and short-run production.
  • CEO: Victoria M. Holt
  • Employees: 2,266
  • Sector: Industrials
  • Industry: Industrial Products
PRLB News
Latest news about the PRLB
  • PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg

    -- VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications – -- U.S. commercial launch of VAZALORE planned for third quarter 2021 -- SPARTA, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products. PLx announced today that the U.S. Food and Drug Administration (“FDA”) approved supplemental new drug applications (“sNDAs”) for its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), the first ever novel, liquid-filled aspirin capsule. “The approval of the VAZALORE sNDAs marks a significant milestone that brings us closer to providing an innovative aspirin to millions of patients who need reliable and predictable antiplatelet therapy,” stated Natasha Giordano, President and Chief Executive Officer of PLx. “We are delighted that the FDA approved both sNDAs for VAZALORE, and we are eager to implement our commercial launch plans later this year. We look forward to introducing VAZALORE to the medical community and to patients who can benefit from this breakthrough technology designed to reduce the risk of stomach injury,” concluded Giordano. In October 2020, the Company submitted separate supplemental new drug applications (“sNDAs”) for each dose strength. The submissions were considered chemistry and manufacturing control (“CMC”) filings as they included information on a change in formulation and the new manufacturing site for VAZALORE 325 mg and a new product strength for the 81 mg dose. The submission for the 325 mg dose also contained the results of a clinical study, demonstrating VAZALORE's bioequivalence to immediate-release aspirin, further supporting the change in formulation. The submission for the 81 mg dose builds off the information in the original approved new drug application, as well as the recent sNDA submitted for VAZALORE 325 mg. About VAZALORE VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. About PLx Pharma Inc.PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx Pharma believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com. Forward-Looking Statements Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property, risks that PLx may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect PLx’s business, financial conditions and results of operations are contained in PLx’s filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov. Other risks and uncertainties are more fully described in PLx’s Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020, and in other filings that PLx has made or will make going forward. The forward-looking statements represent PLx’s estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements. Contact Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: PLx Pharma Inc.

    View More →
  • Did Business Growth Power Proto Labs' (NYSE:PRLB) Share Price Gain of 123%?

    Proto Labs, Inc. ( NYSE:PRLB ) shareholders might be concerned after seeing the share price drop 27% in the last month...

    View More →
  • Why Proto Labs Stock Dropped Tuesday

    Shares of machining, injection-molding, and 3D printing company Proto Labs (NYSE: PRLB) had a volatile day Tuesday. Shares of Proto Labs are down almost 40% from recent highs near the end of January. Proto Labs continues to recover from a difficult business environment in 2020.

    View More →
  • This 3D Printing Stock Stands Out Above Its Rivals

    Motley Fool Co-Chairman David Gardner shares his thoughts on winners and losers among 3D printing stocks.

    View More →
  • Proto Labs Earnings and Revenue Beat Expectations

    The contract manufacturer's Q4 results beat Wall Street's modest estimates, but Q1 revenue guidance came in a bit light.

    View More →
  • Proto Labs Inc (PRLB) Q4 2020 Earnings Call Transcript

    With me today are Proto Labs, President and Chief Executive Officer, Vicki Holt; Vice President and General Manager of the Americas and incoming President and Chief Executive Officer, Rob Bodor; and Chief Financial Officer, John Way. This morning, Proto Labs issued a press release announcing its financial results for the fourth quarter and full-year ended December 31st, 2020.

    View More →
  • Recap: Proto Labs Q4 Earnings

    Shares of Proto Labs (NYSE:PRLB) moved higher by 3.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 20.63% over the past year to $0.50, which beat the estimate of $0.49. Revenue of $105,208,000 decreased by 5.97% year over year, which beat the estimate of $102,450,000. Looking Ahead Earnings guidance hasn't been issued by the company for now. Proto Labs hasn't issued any revenue guidance for the time being. Conference Call Details Date: Feb 12, 2021 View more earnings on PRLB Time: 08:30 AM ET Webcast URL: https://edge.media-server.com/mmc/p/7ayaedkz Price Action Company's 52-week high was at $286.57 Company's 52-week low was at $63.19 Price action over last quarter: Up 75.39% Company Profile Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The largest end market is the United States of America. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 12, 2021Earnings Outlook For Proto Labs© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Proto Labs (PRLB) Surpasses Q4 Earnings and Revenue Estimates

    Proto Labs (PRLB) delivered earnings and revenue surprises of 4.17% and 2.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    View More →
  • Proto Labs, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 12, 2021 / Proto Labs, Inc. (NYSE:PRLB) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 12, 2021 at 8:30 AM Eastern Time.

    View More →
  • Protolabs Reports Financial Results for the Fourth Quarter and Full Year 2020

    Proto Labs, Inc. (NYSE: PRLB), a leading online and technology-enabled, quick-turn on-demand manufacturer, today announced financial results for the fourth quarter and full year ended December 31, 2020.

    View More →
  • Earnings Scheduled For February 12, 2021

    Companies Reporting Before The Bell • Altra Industrial Motion (NASDAQ:AIMC) is projected to report quarterly earnings at $0.69 per share on revenue of $431.76 million. • American Axle & Mfg Hldgs (NYSE:AXL) is projected to report quarterly earnings at $0.28 per share on revenue of $1.36 billion. • CAE (NYSE:CAE) is expected to report quarterly earnings at $0.25 per share on revenue of $611.18 million. • Dominion Energy (NYSE:DCUE) is likely to report earnings for its fourth quarter. • Enbridge (NYSE:ENB) is projected to report quarterly earnings at $0.55 per share on revenue of $10.14 billion. • Moody's (NYSE:MCO) is expected to report quarterly earnings at $1.97 per share on revenue of $1.23 billion. • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $3.97 per share on revenue of $19.52 million. • Sensient Technologies (NYSE:SXT) is estimated to report quarterly earnings at $0.61 per share on revenue of $310.74 million. • Tufin Software (NYSE:TUFN) is likely to report quarterly loss at $0.08 per share on revenue of $29.91 million. • Dominion Energy (NYSE:D) is likely to report quarterly earnings at $0.80 per share on revenue of $4.24 billion. View more earnings on AIMC • Lincoln Electric Holdings (NASDAQ:LECO) is estimated to report quarterly earnings at $1.06 per share on revenue of $685.95 million. • Noble Midstream Partners (NASDAQ:NBLX) is projected to report quarterly earnings at $0.57 per share on revenue of $140.57 million. • W.P. Carey (NYSE:WPC) is expected to report quarterly earnings at $0.47 per share on revenue of $300.73 million. • Banco Latinoamericano (NYSE:BLX) is projected to report earnings for its fourth quarter. • Newell Brands (NASDAQ:NWL) is expected to report quarterly earnings at $0.48 per share on revenue of $2.63 billion. • Immunogen (NASDAQ:IMGN) is likely to report quarterly loss at $0.08 per share on revenue of $40.83 million. • Fortis (NYSE:FTS) is projected to report earnings for its fourth quarter. • Huntsman (NYSE:HUN) is estimated to report quarterly earnings at $0.46 per share on revenue of $1.66 billion. • Proto Labs (NYSE:PRLB) is likely to report quarterly earnings at $0.49 per share on revenue of $102.45 million. Companies Reporting After The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. See more from BenzingaClick here for options trades from BenzingaEarnings Outlook For HuntsmanEarnings Preview for Newell Brands© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Earnings Outlook For Proto Labs

    Proto Labs (NYSE:PRLB) unveils its next round of earnings this Friday, February 12. Get prepared with Benzinga's ultimate preview for Proto Labs's Q4 earnings. Net Income, Earnings, And Earnings Per Share Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS. Earnings And Revenue Wall Street analysts see Proto Labs reporting earnings of $0.49 per share on sales of $102.45 million. Proto Labs earnings in the same period a year ago was $0.63 per share. Quarterly sales came in at $111.89 million. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin. View more earnings on PRLB The analyst consensus estimate would represent a 22.22% decrease in the company's earnings. Sales would be down 8.44% from the year-ago period. Here is how the company's reported EPS has compared to analyst estimates in the past: Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020 EPS Estimate 0.53 0.38 0.38 0.63 EPS Actual 0.67 0.59 0.61 0.63 Revenue Estimate 104.86 M 101.50 M 102.36 M 111.95 M Revenue Actual 107.50 M 106.58 M 115.11 M 111.89 M Stock Performance Shares of Proto Labs were trading at $209.18 as of February 10. Over the last 52-week period, shares are up 112.32%. Given that these returns are generally positive, long-term shareholders are probably content going into this earnings release. Do not be surprised to see the stock move on comments made during its conference call. Proto Labs is scheduled to hold the call at 08:30:00 ET and can be accessed here. See more from BenzingaClick here for options trades from BenzingaEnbridge's Earnings OutlookEarnings Outlook for Sensient Technologies© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Proto Labs to Kick Off 3D Printing Earnings Season: What to Watch

    With its stock up 41% in 2021, the quick-turn contract manufacturer has a lot to prove when it reports Q4 results on Friday.

    View More →
  • 15 Biggest 3D Companies in the World

    In this article we are going to list the 15 biggest 3D companies in the world. Click to skip ahead and jump to the 5 biggest 3D companies in the world. 3D printing is a fairly new and upcoming technique especially in the field of industrial production. Previously, 3D printing was seen as a technique […]

    View More →
  • Earnings Preview: Proto Labs (PRLB) Q4 Earnings Expected to Decline

    Proto Labs (PRLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    View More →
  • Why 3D Printing Stock Proto Labs Surged 38% in January

    Investors liked the digital manufacturer's recent acquisition and deemed good news from rival 3D Systems good news for the industry.

    View More →
  • Protolabs Launches All-new Digital Quoting Platform in U.S.

    Digital manufacturing leader Protolabs (NYSE: PRLB) has launched its new digital quoting and design analysis platform to its U.S.-based customers, following a successful launch late last year to its European-based users.

    View More →
  • New Strong Sell Stocks for February 1st

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

    View More →
  • Why Proto Labs Stock Crashed Back 12.6% Today

    What happened I won't say, "I told you so." In fact, I didn't tell you so -- not outright at least. But in discussing Proto Labs' (NYSE: PRLB) remarkable 12.3% jump in stock price yesterday, I think I at least implied that there wasn't any good reason for it and that investors were lumping in Proto Labs stock with a much different story.

    View More →
  • Why 3D Systems, Stratasys, and Proto Labs Stocks All Popped Today

    On a down day for stock markets, shares of companies involved in the 3D printing business -- additive manufacturing -- are doing just fine. As of 1:45 p.m. EST, shares of 3D Systems (NYSE: DDD) had blasted off to a 16.5% gain, while archrival Stratasys (NASDAQ: SSYS) and 3D prototype manufacturer Proto Labs (NYSE: PRLB) had risen 8.5% and 10.7%, respectively. Specifically, 3D Systems -- the stock that's leading the sector higher today -- announced a "breakthrough in bioprinting technology" today, and an "expansion of regenerative medicine."

    View More →